An Untargeted Metabolomic Study Using MALDI-mass Spectrometry Imaging Reveals Region-specific Biomarkers Associated with Bowel Inflammation

Overview

Journal Metabolomics

Publisher Springer

Specialty Endocrinology

Date 2024 Dec 14

PMID 39674857

Authors

Adele Ponzoni

Silvia Speca

Matthew Hartle

Amandine Gerstenberg

Aurore Tomezyk

Victor Senechal

Shane Karnik

Laurent Dubuquoy

David Launay

Rebecca Deprez-Poulain

Mathieu Gaudin

Corinne Ramos

Benoit Deprez

Affiliations

Soon will be listed here.

Abstract

Introduction: Inflammatory bowel diseases (IBDs) are chronic immune driven intestinal disorders with marked metabolic alteration. Mass spectrometry imaging (MSI) enables the direct visualization of biomolecules within tissues and facilitates the study of metabolic changes. Integrating multiple spatial information sources is a promising approach for discovering new biomarkers and understanding biochemical alteration within the context of the disease.

Objective: This study evaluates the metabolomic changes in gut tissue samples from a preclinical model of spontaneous colitis, the HLA-B27/hβ2m transgenic rat, to uncover disease biomarkers.

Methods: We applied MSI to study the biochemical profile of bowel samples from HLA-B27/hβ2m transgenic and WT control rats in an unbiased manner. Statistical comparison was used to identify discriminative features. Some features were annotated using LC-MS/MS. The significance of these discriminative features was evaluated based on their distribution within histological layers and the presence of immune infiltration.

Results: We identified spatially resolved changes in the metabolomic pattern of HLA-B27 samples compared to WT controls. Out of the 275 discriminative features identified, 83 were annotated as metabolites. Two functional groups of discriminative metabolites were discussed as markers of gut barrier impairment and immune cell infiltration.

Conclusion: MS imaging's spatial dimension provides insights into disease mechanisms through the identification of spatially resolved biomarkers.

References

Neumann E, Djambazova K, Caprioli R, Spraggins J . Multimodal Imaging Mass Spectrometry: Next Generation Molecular Mapping in Biology and Medicine. J Am Soc Mass Spectrom. 2020; 31(12):2401-2415. PMC: 9278956. DOI: 10.1021/jasms.0c00232. View

Demarco V, Li N, Thomas J, West C, Neu J . Glutamine and barrier function in cultured Caco-2 epithelial cell monolayers. J Nutr. 2003; 133(7):2176-9. DOI: 10.1093/jn/133.7.2176. View

Kerr S, Wolyniec W, Filipovic Z, Nodop S, Braza F, Winquist R . Repeated measurement of intestinal permeability as an assessment of colitis severity in HLA-B27 transgenic rats. J Pharmacol Exp Ther. 1999; 291(2):903-10. View

Xie C, Wang Q, Li G, Fan Z, Wang H, Wu X . Dietary supplement with nucleotides in the form of uridine monophosphate or uridine stimulate intestinal development and promote nucleotide transport in weaned piglets. J Sci Food Agric. 2019; 99(13):6108-6113. DOI: 10.1002/jsfa.9850. View

Valibouze C, Speca S, Dubuquoy C, Mourey F, MBa L, Schneider L . prevents postoperative recurrence of Crohn's disease modeled by ileocecal resection in HLA-B27 transgenic rats. World J Gastroenterol. 2023; 29(5):851-866. PMC: 9932430. DOI: 10.3748/wjg.v29.i5.851. View

Wishart D, Tzur D, Knox C, Eisner R, Guo A, Young N . HMDB: the Human Metabolome Database. Nucleic Acids Res. 2007; 35(Database issue):D521-6. PMC: 1899095. DOI: 10.1093/nar/gkl923. View

Novak E, Mollen K . Mitochondrial dysfunction in inflammatory bowel disease. Front Cell Dev Biol. 2015; 3:62. PMC: 4589667. DOI: 10.3389/fcell.2015.00062. View

Hammer R, Maika S, Richardson J, Tang J, Taurog J . Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell. 1990; 63(5):1099-112. DOI: 10.1016/0092-8674(90)90512-d. View

Polanski K, Young M, Miao Z, Meyer K, Teichmann S, Park J . BBKNN: fast batch alignment of single cell transcriptomes. Bioinformatics. 2019; 36(3):964-965. PMC: 9883685. DOI: 10.1093/bioinformatics/btz625. View

10.

Khor B, Gardet A, Xavier R . Genetics and pathogenesis of inflammatory bowel disease. Nature. 2011; 474(7351):307-17. PMC: 3204665. DOI: 10.1038/nature10209. View

11.

Wells J, Brummer R, Derrien M, Macdonald T, Troost F, Cani P . Homeostasis of the gut barrier and potential biomarkers. Am J Physiol Gastrointest Liver Physiol. 2016; 312(3):G171-G193. PMC: 5440615. DOI: 10.1152/ajpgi.00048.2015. View

12.

Bauset C, Gisbert-Ferrandiz L, Cosin-Roger J . Metabolomics as a Promising Resource Identifying Potential Biomarkers for Inflammatory Bowel Disease. J Clin Med. 2021; 10(4). PMC: 7915257. DOI: 10.3390/jcm10040622. View

13.

Xu D, Ma R, Ju Y, Song X, Niu B, Hong W . Cholesterol sulfate alleviates ulcerative colitis by promoting cholesterol biosynthesis in colonic epithelial cells. Nat Commun. 2022; 13(1):4428. PMC: 9338998. DOI: 10.1038/s41467-022-32158-7. View

14.

Smith S, Ogawa S, Chau L, Whelan K, Hamilton K, Chen J . Mitochondrial dysfunction in inflammatory bowel disease alters intestinal epithelial metabolism of hepatic acylcarnitines. J Clin Invest. 2020; 131(1). PMC: 7773399. DOI: 10.1172/JCI133371. View

15.

Gessel M, Norris J, Caprioli R . MALDI imaging mass spectrometry: spatial molecular analysis to enable a new age of discovery. J Proteomics. 2014; 107:71-82. PMC: 4104210. DOI: 10.1016/j.jprot.2014.03.021. View

16.

ODonnell V, Dennis E, Wakelam M, Subramaniam S . LIPID MAPS: Serving the next generation of lipid researchers with tools, resources, data, and training. Sci Signal. 2019; 12(563). DOI: 10.1126/scisignal.aaw2964. View

17.

Schutze S, Potthoff K, Machleidt T, Berkovic D, Wiegmann K, Kronke M . TNF activates NF-kappa B by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown. Cell. 1992; 71(5):765-76. DOI: 10.1016/0092-8674(92)90553-o. View

18.

Mabley J, Pacher P, Liaudet L, Soriano F, Hasko G, Marton A . Inosine reduces inflammation and improves survival in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol. 2002; 284(1):G138-44. DOI: 10.1152/ajpgi.00060.2002. View

19.

Bock J, Liebisch G, Schweimer J, Schmitz G, Rogler G . Exogenous sphingomyelinase causes impaired intestinal epithelial barrier function. World J Gastroenterol. 2007; 13(39):5217-25. PMC: 4171303. DOI: 10.3748/wjg.v13.i39.5217. View

20.

Sevastou I, Kaffe E, Mouratis M, Aidinis V . Lysoglycerophospholipids in chronic inflammatory disorders: the PLA(2)/LPC and ATX/LPA axes. Biochim Biophys Acta. 2012; 1831(1):42-60. DOI: 10.1016/j.bbalip.2012.07.019. View